Education
About Us
Working with TipRanks
Follow Us
Evoke Pharma (EVOK)
NASDAQ:EVOK
Top Page
Evoke Pharma
(NASDAQ:EVOK)
47Neutral
Evoke Pharma (EVOK) vs. S&P 500 (SPY)
Market Cap
$4.17M
Dividend YieldN/A
Average Volume (3M)22.49K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth97.84%
EPS Growth82.99%
CountryUS
Employees3
SectorHealthcare
Sector Strength72
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-4.76
Shares Outstanding1,492,858
10 Day Avg. Volume40,935
30 Day Avg. Volume22,487
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.41
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evoke Pharma Business Overview & Revenue Model
Company DescriptionEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
How the Company Makes MoneyEvoke Pharma generates revenue primarily through the commercialization of its lead product, Gimoti. Revenue is earned from sales of Gimoti to healthcare providers and pharmacies, which is then prescribed to patients suffering from diabetic gastroparesis. The company may also enter into licensing agreements, partnerships, or collaborations with other pharmaceutical firms to broaden the distribution and commercialization of its products. Additionally, Evoke Pharma might receive milestone payments and royalties as part of these agreements, contributing to its earnings. Factors such as market penetration, pricing strategies, and insurance reimbursement policies significantly impact the revenue streams of the company.
Evoke Pharma Financial Statement Overview
Summary
Evoke Pharma's financial statements reveal major challenges: persistent net losses, negative cash flows, and negative equity indicate high financial risk. Despite a significant revenue increase, likely due to a one-time event, profitability and cash generation remain problematic.Income Statement
Evoke Pharma's income statement shows significant challenges, with negative net income across multiple years, indicating sustained losses. Revenue growth between 2023 and 2024 is extraordinary but appears to be an anomaly rather than a trend, likely due to a one-time event or accounting change. However, EBIT and EBITDA margins are negative, highlighting profitability issues.35
Negative
Balance Sheet
The balance sheet indicates a mixed financial position. The debt-to-equity ratio is not calculable for 2024 due to negative equity in 2023, but the presence of substantial cash and equivalents versus debt suggests some liquidity strength. The negative stockholders' equity in previous years is concerning and indicates ongoing financial instability.45
Neutral
Cash Flow
Cash flow analysis reveals a consistent pattern of negative operating and free cash flows, suggesting difficulties in generating cash from operations. However, positive financing cash flows indicate that the company is capable of securing external funding to support its operations, which could be a temporary relief.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.25T | 5.18M | 2.51M | 1.62M | 23.02K | Gross Profit |
| 10.25T | 4.98M | 2.14M | 1.29M | -63.69K | EBIT |
| -5.20T | -7.43M | -7.79M | -8.15M | -13.05M | EBITDA |
| -5.20T | -7.29M | -7.72M | -8.04M | -13.04M | Net Income Common Stockholders |
| -5.35T | -7.79M | -8.16M | -9.03M | -13.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 13.60T | 4.74M | 9.84M | 9.14M | 8.07M | Total Assets |
| 17.52T | 7.07M | 11.85M | 10.57M | 9.43M | Total Debt |
| 5.16M | 5.00M | 5.13M | 5.01M | 5.25M | Net Debt |
| -8.44M | 260.57K | -4.71M | -4.13M | -2.82M | Total Liabilities |
| 10.48T | 9.65M | 7.77M | 7.02M | 12.65M | Stockholders Equity |
| 7.04T | -2.58M | 4.08M | 3.56M | -3.21M |
| Cash Flow | Free Cash Flow | |||
| -5.46T | -4.98M | -6.60M | -12.35M | -6.63M | Operating Cash Flow |
| -5.46T | -4.98M | -6.60M | -12.35M | -6.63M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 14.32T | -119.30K | 7.29M | 13.43M | 9.04M |
Evoke Pharma Technical Analysis
Negative
2.79
Price Trends
4.24
Negative
4.46
Negative
4.96
Negative
Market Momentum
-0.46
Positive
26.13
Positive
25.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVOK, the sentiment is Negative. The current price of 2.79 is below the 20-day moving average (MA) of 3.40, below the 50-day MA of 4.24, and below the 200-day MA of 4.96, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 26.13 is Positive, neither overbought nor oversold. The STOCH value of 25.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVOK.
Evoke Pharma Risk Analysis
Evoke Pharma disclosed 47 risk factors in its most recent earnings report. Evoke Pharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evoke Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $4.06M | ― | -60.76% | ― | -6.20% | 64.07% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
48 Neutral | $4.27M | ― | -229.24% | ― | -1.40% | 91.79% | |
47 Neutral | $4.17M | ― | -240.09% | ― | 97.84% | 82.99% | |
35 Underperform | $4.02M | ― | -285.35% | ― | 674.14% | 89.05% | |
34 Underperform | $4.52M | ― | -91.62% | ― | ― | 48.81% |
* Healthcare Sector Average
Performance Comparison
EVOK
Evoke Pharma
2.79
-4.29
-60.59%
NUWE
Nuwellis
0.98
-12.23
-92.58%
SONN
Sonnet BioTherapeutics Holdings
1.31
-13.81
-91.34%
RKDA
Arcadia Biosciences
2.97
0.92
44.88%
GLTO
Galecto
3.42
-15.20
-81.63%
NLSP
NLS Pharmaceutics
1.30
-5.60
-81.16%
Evoke Pharma Earnings Call Summary
Earnings Call Date: Mar 13, 2025 | % Change Since: -27.34% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, increased prescription fulfillment, and strategic partnerships, contributing to a positive financial outlook for 2025. Despite a net loss and increased expenses, the overall sentiment remains optimistic, bolstered by clinical validation and a strong cash position.Highlights
Record Revenue Growth
Evoke Pharma, Inc. reported a 97% year-over-year increase in revenue, reaching $10.2 million for 2024, up from $5.2 million in 2023.
Increased Prescription Fulfillment
The company achieved a 72% increase in fill rates year over year and a 22% growth in patient enrollments.
Expansion of Prescriber Base
There was a 46% increase in prescribers year over year, bringing the total cumulative prescriber base to 2,553.
Strategic Pharmacy Partnerships
Partnership with Aspen pharmacies facilitated faster delivery and insurance adjudication, contributing to commercial success.
Positive Financial Outlook
Projected net revenue guidance for 2025 is approximately $16 million, representing a 60% increase over 2024.
Strong Cash Position
Cash and cash equivalents were approximately $13.6 million as of December 31, 2024, with a cash runway into the first quarter of 2026.
Clinical Validation and Awards
Gimoti received the presidential poster award at ACT 2024 and demonstrated significant improvement over oral metoclopramide in real-world data.
Lowlights
Net Loss
Evoke Pharma, Inc. reported a net loss of approximately $5.4 million for 2024, though this was an improvement from the $7.8 million loss in 2023.
Increased SG&A Expenses
Selling, general, and administrative expenses rose to $15.1 million in 2024 from $12.2 million in 2023, driven by higher marketing and advertising costs.
Challenges with Prior Authorizations
Only 50% of prior authorizations are being completed, indicating a significant area for improvement.
Company Guidance
During the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call, the company reported strong financial results with total revenue reaching $10.2 million for the year, marking a 97% year-over-year increase. The fourth-quarter revenue was $3.3 million, a 24.6% sequential increase. Significant growth drivers included a 46% increase in prescribers, expanding the cumulative prescriber base to 2,553, and a 72% increase in fill rates. Furthermore, patient enrollments grew by 22%. The company also highlighted the role of its strategic partnership with Aspen pharmacies, contributing to a 30% faster speed to therapy and a substantial reduction in out-of-network prescriptions. Looking forward, Evoke Pharma projects a 60% increase in net revenue for 2025, aiming for approximately $16 million, driven by enhanced reimbursement pathways and increased prescription fills. The company emphasized its commitment to strengthening market position through expanding pharmacy partnerships and increasing provider engagement.Evoke Pharma Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Evoke Pharma Appoints Greg Pyszcymuka as Director
Positive
Feb 24, 2025
On February 20, 2025, Evoke Pharma appointed Greg Pyszcymuka as a Class I director, with his term expiring at the 2026 annual meeting of stockholders. This appointment is part of a strategic move to strengthen the company’s leadership, with Mr. Pyszcymuka bringing over 20 years of experience in sales, marketing, and commercial operations from his previous roles at Aytu Biopharma, Neos Therapeutics, and other pharmaceutical companies. His appointment is expected to enhance Evoke Pharma’s governance and operational strategies.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.